189 related articles for article (PubMed ID: 34020575)
1. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
Bazinet A; Rys RN; Barry A; Greenwood CMT; Young YK; Mendoza A; LaPorta I; Wever CM; Mercier FE; Johnson NA
Leuk Lymphoma; 2021 Oct; 62(10):2352-2359. PubMed ID: 34020575
[TBL] [Abstract][Full Text] [Related]
2. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
3. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
[TBL] [Abstract][Full Text] [Related]
4. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
[TBL] [Abstract][Full Text] [Related]
5. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
7. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
[TBL] [Abstract][Full Text] [Related]
8. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
Goshaw JM; Gao Q; Wardrope J; Dogan A; Roshal M
Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
[TBL] [Abstract][Full Text] [Related]
9. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.
Bento L; Correia R; de Sousa F; Vaz A; Pedro E; Schimidell D; Millan N; Passaro M; Barroso R; Bacal N
Cytometry B Clin Cytom; 2020 Nov; 98(6):529-535. PubMed ID: 32251553
[TBL] [Abstract][Full Text] [Related]
10. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
Nguyen PC; Nguyen V; Baldwin K; Kankanige Y; Blombery P; Came N; Westerman DA
Br J Haematol; 2023 Aug; 202(4):760-770. PubMed ID: 37052611
[TBL] [Abstract][Full Text] [Related]
11. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.
Rawstron AC; Kreuzer KA; Soosapilla A; Spacek M; Stehlikova O; Gambell P; McIver-Brown N; Villamor N; Psarra K; Arroz M; Milani R; de la Serna J; Cedena MT; Jaksic O; Nomdedeu J; Moreno C; Rigolin GM; Cuneo A; Johansen P; Johnsen HE; Rosenquist R; Niemann CU; Kern W; Westerman D; Trneny M; Mulligan S; Doubek M; Pospisilova S; Hillmen P; Oscier D; Hallek M; Ghia P; Montserrat E
Cytometry B Clin Cytom; 2018 Jan; 94(1):121-128. PubMed ID: 29024461
[TBL] [Abstract][Full Text] [Related]
12. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
13. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of immunophenotype characteristics in 109 cases of B lineage chronic B lymphoid leukemia].
Wang AQ; Geng MJ; Zhu MQ; Chen L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1374-7. PubMed ID: 22169286
[TBL] [Abstract][Full Text] [Related]
15. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
Keeney M; Halley JG; Rhoads DD; Ansari MQ; Kussick SJ; Karlon WJ; Mehta KU; Dorfman DM; Linden MA
Arch Pathol Lab Med; 2015 Oct; 139(10):1276-80. PubMed ID: 25695342
[TBL] [Abstract][Full Text] [Related]
16. Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.
Gao Q; Roshal M
Curr Protoc; 2022 Aug; 2(8):e503. PubMed ID: 35980134
[TBL] [Abstract][Full Text] [Related]
17. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
Garcia Vela J; Delgado I; Benito L; Monteserin M; Garcia Alonso L; Somolinos N; Andreu M; Oña F
Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
[TBL] [Abstract][Full Text] [Related]
18. Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
Brett VE; Dilhuydy MS; Lechevalier N; Adjibabi AN; Gros FX; Forcade É; Letestu R; Vial JP
Ann Biol Clin (Paris); 2023 Oct; 81(4):379-387. PubMed ID: 37864443
[TBL] [Abstract][Full Text] [Related]
19. Efficiency and Health Economic Evaluations of BD OneFlow™ Flow Cytometry Reagents for Diagnosing Chronic Lymphoid Leukemia.
Moloney E; Watson H; Barge D; Allen AJ; Carey P; Hislop J; Johnston L; Lorrison K; McGregor A; O'Leary RA; Power MH; Wallis J; Simpson AJ; Greystoke B
Cytometry B Clin Cytom; 2019 Nov; 96(6):514-520. PubMed ID: 30941899
[TBL] [Abstract][Full Text] [Related]
20. Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods.
Böttcher S
Methods Mol Biol; 2019; 1881():211-238. PubMed ID: 30350209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
